Skip to main content
OpenTrials
Completed

NCT Number: NCT01147172

Safety Study of Cosmetic Tissue Augmentation in People of Color

Elevess is intended for all skin types. However, further study of all soft tissue fillers is needed in people of color because of the increasing use of cosmetic dermal filler products.

This study is designed to evaluate the safety of an injectable hyaluronic acid based dermal filler Elevess (Anika Therapeutics, Inc., Bedford, MA). Safety will be evaluated by incidence and severity of keloid formation and pigmentation changes, and other potential adverse events in people with Fitzpatrick skin types IV, V and VI who have elected to undergo nasolabial fold (NLF) treatment with Elevess.

1. Fitzpatrick Classification of Skin Type as: IV - Burns minimally, always tans well (moderate/light brown skin; Mediterranean, Asian, Hispanic. V - Rarely burns, tans profusely (dark brown/brown skin: Middle eastern, Latin, light skinned Black, Indian) VI - Never burns, (deeply pigmented dark brown to black skin;Black)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Wrinkles

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Vitiligo and Pigmentation Inst of Southern California, Los Angeles, California, United States

Loading trial locations.

About this study

This study is designed to be an open-label, longitudinal, uncontrolled study in a minimum of 100 subjects with Fitzpatrick scale skin type of IV, V or VI at 10 or more U.S. centers who have elected to undergo NLF treatment with intradermal (deep dermal) injection of Elevess. Subjects will be followed for a minimum of 24 weeks with visit assessments at 2, 6, 12 and 24 weeks after the last injection.

Safety: Primary Safety Endpoint assessments will be: 1) keloid formation at the site of injection at 2, 6, 12 and 24 weeks, 2) pigmentation changes at the site of injection compared to adjacent skin at 2, 6, 12 and 24 weeks, and 3) overall adverse events. A subject diary will also be collected.

Effectiveness: No formal effectiveness evaluation will be performed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Fitzpatrick skin type of IV, V or VI.
  • Bilateral nasolabial folds which, in the investigator's judgment, can be corrected with Elevess.
  • Age greater or equal to 18 years.

Exclusion criteria

  • Fitzpatrick skin type of I, II or III.
  • Subject has severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies.
  • Subject has allergies to the components of Elevess: hyaluronic acid, lidocaine, sodium metabisulfite or gram positive bacterial proteins.
  • Subject has a history of severe keloids and/or hypertrophic scars.
  • Subject has ever received any soft tissue augmentation in any area of the face and subject is unwilling to forgo all other soft tissue augmentation for the duration of the study.
  • Subject has received any aesthetic or dermatologic treatments or procedures in any area of the face in the previous 6 months and subject is unwilling to forgo such treatments or procedures for the duration of the study.
  • Subject has active facial acne lesions, severe acne scarring or pigmentation disorders at the injection site that might affect clinical assessment of the nasolabial folds.
  • Subject has ever received an injection or implant of silicone in any area of the face.
  • Subject has received immunosuppressive therapy, chemotherapy, or systemic corticosteroids within the last 3 months.
  • Subject has a history of a connective tissue disease.
  • Subject is positive for HIV/AIDS or hepatitis C.
  • Subject is involved in any other research study involving an investigational product (drug, device or biologic) or a new application of an approved product, within 30 days of screening

Treatment and study plan

Elevess

Device

Injectable gel, 0.5mL or 1.0mL material supplied in a 1.0mL pre-filled sterile glass syringe with two 30 gauge needles

Primary outcomes

  1. Keloid Formation at Site of Injection

    Time frame: 2 Weeks

    Percentage of Subjects with keloid formation at the site of injection

  2. Keloid Formation at Site of Injection

    Time frame: 6 Weeks

    Percentage of Subjects with keloid formation at the site of injection

  3. Keloid Formation at Site of Injection

    Time frame: 12 Weeks

    Percentage of Subjects with keloid formation at the site of injection

  4. Keloid Formation at Site of Injection

    Time frame: 24 Weeks

    Percentage of subjects with keloid formation at the site of injection at End of Study

  5. Pigmentation Changes at Site of Injection

    Time frame: 2 Weeks

    Percentage of Subjects with pigmentation changes at site of injection

  6. Pigmentation Changes at Site of Injection

    Time frame: 6 Weeks

    Percentage of Subjects with pigmentation changes at site of injection

  7. Pigmentation Changes at Site of Injection

    Time frame: 12 Weeks

    Percentage of Subjects with pigmentation changes at site of injection

  8. Pigmentation Changes at Site of Injection

    Time frame: 24 Weeks

    Percentage of subjects with pigmentation changes at site of injection at End of Study

Sponsors and collaborators

Lead sponsor

Anika Therapeutics, Inc.

Industry

Registry information

Official study title

A Post Approval, Multicenter, Open-Label, Longitudinal, Uncontrolled Safety Study of Cosmetic Tissue Augmentation Product (ELEVESS™) in the Treatment of Nasolabial Folds in People of Color

Important dates

Study start
2009
Primary completion
2009
Study completion
2010
First posted
Jun 22, 2010
Registry last updated
Oct 17, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.